Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
Pacira BioSciences (NASDAQ: PCRX), a leader in non-opioid pain therapies, will release its second quarter 2025 financial results after U.S. markets close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. ET the same day. Participants can pre-register for the Q&A session via telephone, while the webcast will be accessible through the "Events" page on Pacira's investor website. A replay will be available for approximately two weeks following the call.
Pacira BioSciences (NASDAQ: PCRX), leader nelle terapie per il dolore non oppioidi, pubblicherà i suoi risultati finanziari del secondo trimestre 2025 dopo la chiusura dei mercati statunitensi, martedì 5 agosto 2025.
La società terrà una conference call e una webcast alle 16:30 ET dello stesso giorno. I partecipanti possono preregistrarsi per la sessione di domande e risposte via telefono, mentre la webcast sarà disponibile attraverso la pagina "Eventi" sul sito degli investitori di Pacira. Una registrazione sarà accessibile per circa due settimane dopo la chiamata.
Pacira BioSciences (NASDAQ: PCRX), líder en terapias para el dolor sin opioides, publicará sus resultados financieros del segundo trimestre de 2025 tras el cierre de los mercados estadounidenses el martes 5 de agosto de 2025.
La compañía realizará una llamada conferencia y una transmisión en vivo a las 4:30 p.m. ET ese mismo día. Los participantes pueden pre-registrarse para la sesión de preguntas y respuestas por teléfono, mientras que la transmisión estará disponible en la página de "Eventos" del sitio web para inversores de Pacira. Una repetición estará disponible durante aproximadamente dos semanas después de la llamada.
Pacira BioSciences (NASDAQ: PCRX)는 비오피오이드 진통제 분야의 선두주자로, 2025년 2분기 재무 결과를 미국 시장 마감 후인 2025년 8월 5일 화요일에 발표할 예정입니다.
같은 날 오후 4시 30분(동부시간)에 컨퍼런스 콜과 웹캐스트를 진행합니다. 참가자들은 전화로 Q&A 세션 사전 등록이 가능하며, 웹캐스트는 Pacira 투자자 웹사이트의 "이벤트" 페이지를 통해 접속할 수 있습니다. 콜 이후 약 2주간 다시보기 서비스가 제공됩니다.
Pacira BioSciences (NASDAQ : PCRX), un leader des thérapies contre la douleur non opioïdes, publiera ses résultats financiers du deuxième trimestre 2025 après la clôture des marchés américains, le mardi 5 août 2025.
L'entreprise organisera une conférence téléphonique et une diffusion en direct à 16h30 ET le même jour. Les participants peuvent s'inscrire à l'avance pour la session de questions-réponses par téléphone, tandis que la diffusion sera accessible via la page « Événements » du site des investisseurs de Pacira. Un replay sera disponible pendant environ deux semaines après l'appel.
Pacira BioSciences (NASDAQ: PCRX), ein führendes Unternehmen für nicht-opioide Schmerztherapien, wird seine Finanzergebnisse für das zweite Quartal 2025 nach Börsenschluss in den USA am Dienstag, den 5. August 2025, veröffentlichen.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten. Teilnehmer können sich telefonisch für die Fragerunde voranmelden, während der Webcast über die „Events“-Seite auf der Investorenseite von Pacira zugänglich sein wird. Eine Aufzeichnung wird etwa zwei Wochen nach dem Anruf verfügbar sein.
- None.
- None.
BRISBANE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday August 5, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com. For those unable to participate in the live call, a replay of the webcast will be available on the Pacira website for approximately two weeks following the call.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Pacira BioSciences, Inc. Christian Pedetti, (973) 254-4387 Christian.Pedetti@pacira.com
FAQ
When will Pacira (PCRX) report Q2 2025 earnings?
What time is Pacira's Q2 2025 earnings conference call?
How can investors access Pacira's Q2 2025 earnings call?
How long will Pacira's Q2 2025 earnings call replay be available?
